Psychedelic drug developers

Enveric Biosciences

Nasdaq: ENVB · Cambridge, MA · Website

$1.52

−0.33% (−$0.01) on the day

Close Nov 13, 2026

Market cap

$6.76M

1 month

+8.99%

52-week range

$1.17–$13.25

Last month

Why we cover it

Builds chemically modified psilocybin analogs (its EVM-301 series) designed to keep the brain-rewiring effect without the hallucinations. Holds 12 granted and 18 pending patents, all around psilocybin.

Financials

Cash & equivalents	$5.61M	as of Sep 30, 2026 · 10-Q
Research & development	$1.35M	quarter ended Sep 30, 2026 · 10-Q
Net income (loss)	−$2.55M	quarter ended Sep 30, 2026 · 10-Q

From the company's SEC filings. See all filings ↗

Patents Patent tracker

Holder	Compounds	Granted	Pending	Expire
Enveric Biosciences Canada Inc	Psilocybin	12	18	2042–2044

News (1)

Aug 20, 2026 New on Altitude: Who Actually Holds Psilocybin's 223 Patents

In the Journal (2)

Aug 20, 2026 Psilocybin Has 223 Patents in Play. Here's Who Actually Holds Them.
Aug 17, 2026 677 Patents and One FDA Rejection: Mapping the Psychedelic Drug Pipeline

Prices are end-of-day closes from Nasdaq; financials come from SEC filings. Not investment advice.